During each visit, patient data were collected in a common database (ARTHROS) by a clinician trained in the program. At the coordinating center, strict control and supervision of the data received was undertaken, with permanent communication with the submitting center for any queries arising and/or missing data.
History, physical examination and laboratory tests were performed at entry and at all subsequent visits, which took place every six months after the initial visit. Medications taken were also noted; however, the precise data on their average and cumulative dose were not obtained. The average follow-up time was 4.3 years. Ethnicity was defined according to the parents' and all four grandparents' selfreported ethnicity. The following ethnic groups were considered: Caucasian (individuals with all white European ancestors), Mestizo (individuals born in Latin America who had both Amerindian and white ancestors), African-Latin American (ALA) (individuals born in Latin America with at least one African ancestor whether other ancestors were white or not) and other. In short, we used self-reported ethnic definitions rather than ancestry-informative markers (AIMs) to define the different ethnic groups. Socioeconomic status was evaluated using the Graffar index [16] . Disease activity was ascertained with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [17] at all visits. Damage was assessed at yearly intervals with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) [18] .
The local ethics committee of each participating center approved the protocol.
Statistical analysis
The socioeconomic, demographic, clinical and laboratory features of patients with and without cutaneous manifestations at any time during the disease course were compared with Pearson Chi squared or Fisher's exact tests for proportions, and the Students t-test for continuous data. The odds ratio (OR) and the 95% confidence interval (CI) were calculated using univariable logistic regression. A p value equal or less than 0.05 was considered statistically significant; variables significant in these analyses were included in a multivariable logistic regression adjusting for gender, age, the average SLEDAI score and the last SDI score excluding cutaneous manifestations. Univariable and multivariable analyses to assess whether cutaneous manifestations are predictors of subsequent occurrence of other clinical manifestations were also performed. For these analyses, only the cutaneous manifestations present before fulfillment of diagnostic criteria were included but not the ones that appeared after the fulfillment of these criteria; recurrences were also excluded.
The different immunological laboratory tests had not been obtained in all patients. Antinuclear antibodies (ANA), anti-DNA antibodies and complement had not been performed in about 15% of the patients; however, the proportion of patients with missing data was comparable in those with and without cutaneous manifestations, so that, the original data were used. The anti-RNP, anti-Sm, anti-La, anti-Ro and anti-cardiolipin antibodies had not performed in about 30% of the patients; however, no significant difference was observed in the proportion of patients with missing data between patients with and without all cutaneous manifestations so again the original data were used. However, the lupus anticoagulant and anti-β2 glycoprotein 1 test had been performed in less than 50% of the patients and thus both tests were excluded from the analyses.
All analyses were carried out using SPSS, version 19 (Chicago Illinois).
Introduction
Systemic lupus erythematosus (SLE) is a chronic, autoimmune, inflammatory disease which is quite heterogeneous in its clinical manifestations. Cutaneous manifestations occur in 50% to 85% [1] [2] [3] [4] [5] [6] [7] [8] of SLE patients making the skin the most commonly affected organ and the most frequent target of initial clinical manifestations following joint involvement [9, 10] .
Cutaneous manifestations are indeed important features of SLE and have always been included in the classification criteria of this disease. For example, in the revised and updated American College of Rheumatology (ACR) classification criteria lesions such as malar rash, discoid rash, photosensitivity, and oral ulcers had a high specificity for SLE [11, 12] . In the recently published SLICC (Systemic Lupus Erythematosus International Collaborating Clinics) criteria, mucocutaneous manifestations otherwise not considered in these previous ACR criteria, such as subacute cutaneous lupus, bullous lupus, lupus panniculitis, scarring alopecia and others were included [13] .
In spite of their overall benign appearance, skin lesions may significantly affect the patients' self-esteem, quality of life and job performance [14] . Regardless of gender, skin lesions do affect the patients' self-esteem and may be accompanied by variable degrees of emotional distress [15] .
The purpose of the present study was to assess the prevalence of cutaneous manifestations occurring over the course of SLE and their associated features, as well as to evaluate whether cutaneous manifestations are predictive of the occurrence of other clinical manifestations in a Latin American Lupus cohort.
Material and Methods
GLADEL (Grupo Latino Americano De Estudio del Lupus) was established in 1997 as an observational inception lupus cohort constituted by 34 centers distributed among nine Latin American countries. Patients were included with a recent SLE diagnosis (less than two years); fulfillment of four ACR 1982 SLE criteria was not mandatory at enrollment [11] , however, 96.0% of patients fulfilled these criteria during their follow-up. In order to have a balanced representation of centers in the initial cohort, each center was asked to incorporate a minimum of 20 and a maximum of 30 randomly selected patients. Randomization was done locally at each center. The first patients were entered in October 1997, and to insure their recent onset they could only be included if the diagnosis of SLE had been made after January 1 st 1996 by a rheumatologist or a qualified internist with experience in SLE. After incorporating the initial 30 patients, each group continued to include one new randomly selected patient per month diagnosed within the previous two years. Patients were invited to participate by their treating physician and an informed consent was signed and saved at each participating center. Each patient was interviewed and her or his medical record's information was validated. All researchers followed local regulations according to their institutional review boards.
(83.1% vs 69.9%, p = 0.002) and musculoskeletal manifestations (93.5% vs. 83.9%, p = 0.002) and anti-Ro antibody positivity (52.5% vs. 31.7%, p = 0.015) but less frequently in those with pleuropulmonary involvement (27.5% vs. 43.0%, p = 0.002). Cutaneous manifestations were protective of the subsequent occurrence of pleuropulmonary (OR 0.519, 95% CI 0.372-0.724) and hematological (OR 0.621, 95% CI 0.440-0.876) manifestations.
Conclusions:
Cutaneous manifestations occur frequently and early in SLE. They were associated with female gender, the presence of systemic and musculoskeletal manifestations and antiRo antibody positivity. They were protective of the development pleuropulmonary and hematologic manifestations.
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Systemic lupus erythematosus, Clinical manifestations, Epidemiology fulfilling the four SLE classification criteria. Most patients had more than one type of skin lesion; the most common manifestations were malar rash 65.0%, alopecia 63.0%, photosensitivity 59.5% and oral ulcers 44.7%. The frequency of each type of cutaneous manifestation is shown in figure 1. 
Multivariable analysis
The results of the multivariable analysis are also shown in 
Discussion
This is the first report on a large number of Latin American SLE patients that describes the cutaneous manifestations of the disease and reflects the reality of daily clinical practice among them. A very high frequency of cutaneous manifestations (93.7%) was observed in this GLADEL cohort; this is even higher than the frequencies described by Dubois, et al. and Harvey, et al. in US patients [3, 4] , and those found in studies of European (59%), Iranian and Pakistani (82%) populations [2, 6, 7] . However, the frequency found in our cohort is similar to that found in Brazilians where cutaneous manifestations occurred in over 90% of the patients being the most common malar rash and photosensitivity [19] . A sustained exposure to ultraviolet light among our Latin American patients could be the explanation for these findings. The most frequent manifestations we observed were malar rash, alopecia, photosensitivity and Raynaud phenomenon, similar to what has been described in many other previous studies [6, 8, [20] [21] [22] [23] [24] .
Cutaneous manifestations were associated with a higher frequency of systemic manifestations and musculoskeletal manifestations, the latter being the other most common manifestation of the disease; this is, somewhat similar to a study conducted in Spain, in which patients with subacute cutaneous lesions presented arthralgia and systemic manifestations more frequently than patients with chronic cutaneous manifestations [25] .
An important finding of our study was the occurrence of a lower frequency of cardiac and pleuropulmonary manifestations in patients with cutaneous involvement; these data, reinforce a previous report [26] . Furthermore, cutaneous manifestations were protective of the subsequent occurrence of hematologic and pleuropulmonary manifestations, fact which has not previously been reported. A protective effect for the occurrence of renal manifestations was not found in our study; however we have previously found discoid lupus (occurring at disease onset) to be protective of the subsequent development of lupus nephritis [27] and that patients with photosensitivity experience a longer time to the occurrence of renal disease [28] . This apparent discrepancy probably relates to the fact that we have examined all cutaneous manifestations together and not individually.
Although we found a higher frequency of patients with a SLEDAI ≥ 4 in those with cutaneous manifestations, this association is of questionable value since these manifestations were not excluded from the SLEDAI; nevertheless, we have included the SLEDAI score in the multivariable analyses as an adjustment variable.
It is widely accepted that anti-Ro antibodies, produced by the exposure of self-antigens from the cell surfaces to ultraviolet B radiation [29] , play a role in the pathogenesis of skin lesions association which we have confirmed. Other authors have found these antibodies to be associated with photosensitive rashes, alopecia and subacute cutaneous lesions [8, 25, 30, 31] . It should be noted however, that no relationship between the different skin rashes and the presence of certain antibodies, including anti-Ro has been found in patients of African descend [32] .
Anti-RNP antibodies positivity has been associated with cutaneous manifestations; Grönhagen, et al. found these antibodies to be associated with acute cutaneous lesions in a study of 260 SLE patients [7] . Anticardiolipin antibodies positivity has been associated with the occurrence of Raynaud phenomenon and livedo reticularis, among others; these manifestations are well-known components of the antiphospholipid syndrome and have also been associated with anti-Beta 2 glycoprotein 1 antibodies positivity [7] . Hypocomplementaemia was not associated with the presence of cutaneous manifestations; however, other authors have reported hypocomplementemia to be associated primarily with cutaneous vasculitis [33] . However, we have not examined these association because of the paucity of data about complement levels and the fact that we have examined all cutaneous manifestations together.
The association of cutaneous manifestations with the use of antimalarials, more than likely reflects the fact that their presence is a clear indication for therapy with these compounds as has been widely reported and recognized [1, [34] [35] [36] ].
An important limitation of our study is that the association of skin lesions and some auto-antibodies could not be examined since they were not available in all patients, had not been obtained at a central laboratory or at the time cutaneous manifestations occurred. This prevents us from making a definitive interpretation of some of the associations we are reporting. Another limitation is that the diagnosis of cutaneous manifestations has not been carried out systematically by dermatologists; however, all patients have been evaluated by rheumatologists trained and experienced in the recognition of cutaneous manifestations of SLE. Finally, we could not examine the relationship between these manifestations and the average and cumulative doses of the drugs used since this detailed information had not been obtained. Nevertheless, we think that the data being reported is quite valuable.
In conclusion, cutaneous manifestations occur quite frequently in Latin American SLE patients and they appear to be an early manifestation of the disease. The most frequent manifestations were malar erythema, alopecia and photosensitivity. Cutaneous manifestations were associated with the presence of systemic and musculoskeletal manifestations and positive anti-Ro antibodies; they were, however, inversely associated with the presence of pleuropulmonary manifestations. Finally, they were protective of the occurrence of pleuropulmonary and hematologic manifestations.
